These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 7538236)

  • 1. Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era.
    McCormack RT; Rittenhouse HG; Finlay JA; Sokoloff RL; Wang TJ; Wolfert RL; Lilja H; Oesterling JE
    Urology; 1995 May; 45(5):729-44. PubMed ID: 7538236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific antigen (hK3) and human prostatic glandular kallikrein (hK2) in the detection of early stage human prostate cancer.
    Wilson MJ
    J Lab Clin Med; 1998 Apr; 131(4):298-9. PubMed ID: 9579381
    [No Abstract]   [Full Text] [Related]  

  • 3. Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate.
    Rittenhouse HG; Finlay JA; Mikolajczyk SD; Partin AW
    Crit Rev Clin Lab Sci; 1998 Aug; 35(4):275-368. PubMed ID: 9759557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of monoclonal antibodies specific for human glandular kallikrein (hK2): development of a dual antibody immunoassay for hK2 with negligible prostate-specific antigen cross-reactivity.
    Finlay JA; Evans CL; Day JR; Payne JK; Mikolajczyk SD; Millar LS; Kuus-Reichel K; Wolfert RL; Rittenhouse HG
    Urology; 1998 May; 51(5):804-9. PubMed ID: 9610595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural comparison of prostate-specific antigen and human glandular kallikrein using molecular modeling.
    Bridon DP; Dowell BL
    Urology; 1995 May; 45(5):801-6. PubMed ID: 7538242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular forms of prostate-specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancer.
    Pannek J; Rittenhouse HG; Evans CL; Finlay JA; Bruzek DJ; Cox JL; Chan DW; Subong EN; Partin AW
    Urology; 1997 Nov; 50(5):715-21. PubMed ID: 9372881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker.
    Darson MF; Pacelli A; Roche P; Rittenhouse HG; Wolfert RL; Young CY; Klee GG; Tindall DJ; Bostwick DG
    Urology; 1997 Jun; 49(6):857-62. PubMed ID: 9187691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
    Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
    Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of prostate specific antigen density to improve the sensitivity of prostate specific antigen in detecting prostate carcinoma.
    Bretton PR; Evans WP; Borden JD; Castellanos RD
    Cancer; 1994 Dec; 74(11):2991-5. PubMed ID: 7525040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate.
    Oesterling JE
    J Urol; 1991 May; 145(5):907-23. PubMed ID: 1707989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
    Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen and human glandular kallikrein: two kallikreins of the human prostate.
    Henttu P; Vihko P
    Ann Med; 1994 Jun; 26(3):157-64. PubMed ID: 7521173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA.
    Scorilas A; Plebani M; Mazza S; Basso D; Soosaipillai AR; Katsaros N; Pagano F; Diamandis EP
    Prostate; 2003 Feb; 54(3):220-9. PubMed ID: 12518327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human Kallikrein-2, Prostate Specific Antigen and Free- Prostate Specific Antigen in Combination to Discriminate Prostate Cancer from Benign Diseases in Syrian Patients.
    Bachour DM; Chahin E; Al-Fahoum S
    Asian Pac J Cancer Prev; 2015; 16(16):7085-8. PubMed ID: 26514494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of circulating prostate cells by reverse transcriptase-polymerase chain reaction of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) messages.
    Corey E; Arfman EW; Oswin MM; Melchior SW; Tindall DJ; Young CY; Ellis WJ; Vessella RL
    Urology; 1997 Aug; 50(2):184-8. PubMed ID: 9255285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
    Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
    J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Huber A; Lümmen G; Tscholl R
    Urology; 2000 Apr; 55(4):481-5. PubMed ID: 10736487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kallikreins as biomarkers for prostate cancer.
    Hong SK
    Biomed Res Int; 2014; 2014():526341. PubMed ID: 24809052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios.
    Oesterling JE; Jacobsen SJ; Klee GG; Pettersson K; Piironen T; Abrahamsson PA; Stenman UH; Dowell B; Lövgren T; Lilja H
    J Urol; 1995 Sep; 154(3):1090-5. PubMed ID: 7543605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Classification analyses for prostate cancer, benign prostate hyperplasia and healthy subjects by SERS-based immunoassay of multiple tumour markers.
    Zhou L; Liu Y; Wang F; Jia Z; Zhou J; Jiang T; Petti L; Chen Y; Xiong Q; Wang X
    Talanta; 2018 Oct; 188():238-244. PubMed ID: 30029370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.